Abstract:Lung cancer remains one of the leading causes of death worldwide. Due to the side effects of chemotherapeutic agents on normal cells and the development of resistance by cancer cells, there is an urgent need for alternative new pharmacological agents. Palladium (Pd)-conjugated Schiff base (SB) compounds represent an alternative approach with promising potential applications in cancer treatment. This study aims to identify novel therapeutic agents on A549 cells through the synthesis and characterization of Schiff base conjugated-Palladium complexes (Pd-L1 and Pd-L2). Additionally, it seeks to elucidate the mechanism of action of these compounds on both the A549 and NIH/3T3 cell lines. In the present study, two new Pd-L1 and Pd-L2 were synthesized for the first time and characterized mainly by single crystal X-ray diffraction and 1H, 13C, 31P NMR techniques. The cytotoxic effect of the compounds was evaluated by MTT assay on A549 and NIH/3T3 cell lines for 24 and 48 h. Cisplatin was used as a positive control group. Based on the cytotoxicity results, the complexes were evaluated for their anticancer activities against A549 cell lines for 48 h through reactive oxygen species (ROS), cell cycle, apoptotic, and necrotic cell analyses. The most potent cytotoxic effects were determined for Pd-L1 (IC50: 23.33 μM), Pd-L2 (IC50: 3.19 μM), and cisplatin (IC50: 33.27 μM) on A549 cells (p < 0.05). The compounds exhibited a significant cytotoxic effect at lower concentrations on A549 cells compared to NIH/3T3 cells (p < 0.05). All compounds showed a significant increase in ROS levels in A549 cells compared to the control group (p < 0.05). While necrosis and apoptosis was observed in A549 cells treated with cisplatin, induction of apoptosis was effective in cell death for A549 cells treated with Pd-L1 and Pd-L2 (p < 0.05). Additionally, it was observed that the compounds inhibited cell proliferation in the G0/G1 and G2/M cell cycle phases (p < 0.05). All compounds induced cell cycle arrest and cell death in A549 cells by increasing ROS levels. The results obtained in the present study could advance the utilization of the compounds as anticancer agents.

Pharmacokinetics and Tissue Distribution of Two Novel Isomerism Anticancer Platinum Compounds

Pharmacokinetics and Tissue Distribution in Rats of a Novel Anticancer Platinum Compound LLC-1903

Investigation on Pharmacokinetics, Tissue Distribution and Excretion of a Novel Anticancer Platinum Compound by Inductively Coupled Plasma Mass Spectrometry after Intravenous Administration to Rats

Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors Via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

Synthesis and mechanistic studies of novel spin-labeled combretastatin derivatives as potential antineoplastic agents.

Effect of geometric isomerism on the anticancer property of new platinum complexes with glycine derivatives as asymmetric N, O donate ligands against human cancer

Antitumor Agents 288: Design, Synthesis, SAR, and Biological Studies of Novel Heteroatom-Incorporated Antofine and Cryptopleurine Analogues As Potent and Selective Antitumor Agents.

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Synthesis and Antitumor Activity of (3-Hydroxyacrylato-o,o′) Diammineplatinum(II)

Synthesis, Characterization and Antitumor Activity of New Type Binuclear Platinum(ii) Complexes.

Application Of High Performance Capillary Electrophoresis Tandem Mass Spectrometry To The Investigation On The Stability Of Novel Anticancer Platinum Complex In Solution

Preclinical Pharmacokinetics and Biodistribution of Anticancer Dinuclear Palladium(II)-Spermine Complex (Pd2Spm) in Mice

Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum IV Complexes as Potent Antitumor Agents

Anticancer Effect of PtIIPHEN SS, PtII5ME SS, PtII56ME SS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer

Synthesis and Cytotoxic Evaluation of Novel Platinum(Ii) Complexes with C2-Asymmetric and C2-Symmetric Chiral Vicinal Diamines

Design, Synthesis and Biological Evaluation of a Novel Platinum(ii) Complex Possessing Bioreductive Groups for Cancer Therapy

Investigation of the anticancer effect of newly synthesized palladium conjugate Schiff base metal complexes on non-small cell lung cancer cell line and mouse embryonic fibroblast cell line

Development of a Highly In Vivo Efficacious Dual Antitumor and Antiangiogenic Organoiridium Complex as a Potential Anti-Lung Cancer Agent

Synthesis and in Vitro Antitumor Activity of Novel Iridium(iii) Complexes with Enantiopure C2-symmetrical Vicinal Diamine Ligands

The Synthesis and Pharmacokinetics of a Novel Liver-Targeting Cholic Acid-Conjugated Carboplatin in Rats

Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism